Hepatitis C Articles (HCV)
Back
	HCV New drugs Latest Updates       Global HCV Access & Eradication - (12/20/13)   Roche at AASLD - (11/26/13)   New HCV Treatments - (11/25/13)   Simeprevir (Olysio) J & J Patient Access Programs Sofosbuvir (Sovaldi) - Gilead U.S. Patient Assistance Program   GILEAD ANNOUNCES SVR12 RATES FROM THREE PHASE 3 STUDIES EVALUATING A ONCE-DAILY FIXED-DOSE COMBINATION OF SOFOSBUVIR AND LEDIPASVIR FOR GENOTYPE 1 HEPATITIS C PATIENTS - For Immediate Release - (12/18/13)   ABBVIE DEMONSTRATES 96 PERCENT SVR(12) IN ITS PHASE III STUDY OF TREATMENT-EXPERIENCED PATIENTS WITH GENOTYPE 1 HEPATITIS C - (12/18/13)   AbbVie Releases First of Six Phase III Results from Investigational All-Oral, Interferon-Free, 12-week Regimen, Showing 96 Percent SVR12 in Genotype 1 Hepatitis C Patients New to Therapy - (11/18/13)   Olysio (Simeprevir): FDA (preliminary prescribing information; summary of the basis of approval and highlights from the prescribing information - (11/26/13)   Hep C Articles...   AASLD: Summary from AASLD 2013 for Hepatitis C Washington 1-5 November 2013 - Written by Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany   HEPDART 2013: Frontiers in Drug Development for Viral Hepatitis December 8-12, 2013 Big Island, Hawaii   AASLD: Gilead at AASLD: 2 - (11/18/13)   AASLD: BMS at AASLD - (11/18/13)   AASLD: Boehringer Ingelheim - (11/18/13)   AASLD: Merck at AASLD - (11/18/13)   AASLD: Janssen at AASLD - (11/18/13)   AASLD: Abbvie at AASLD - (11/18/13)   64rd Annual Meeting of the American Association for the Study of Liver Diseases Washington, DC Nov 1-5 2013           View Older Articles   Back to Top   www.natap.org